Search | OpenScholar

Search results

170 results found

Pimavanserin treatment for Parkinson's disease psychosis in clinical practice. Parkinsons Dis 2021:2603641. doi: 10.1155/2021/2603641.

Publication: Journal Article

Dashtipour, K, F Gupta, RA Hauser, CA Krunapuzha, and JC Morgan. 2021. “Pimavanserin Treatment for Parkinson’s Disease Psychosis in Clinical Practice. Parkinsons Dis 2021:2603641. Doi: 10.1155/2021/2603641.”. Parkinsons Dis.

Amantadine ER (Gocovri®) Significantly Increases ON Time Without Any Dyskinesia: Pooled Analyses From Pivotal Trials in Parkinson's Disease. Front Neurol. 2021 Mar 26;12:645706. doi: 10.3389/fneur.2021.645706. eCollection 2021.PMID: 33841311.

Publication: Journal Article

Hauser, RA, RR Walsh, R Pahwa, D Chernick, and AE Formella. 2021. “Amantadine ER (Gocovri®) Significantly Increases ON Time Without Any Dyskinesia: Pooled Analyses From Pivotal Trials in Parkinson’s Disease. Front Neurol. 2021 Mar 26;12:645706. Doi: 10.3389/Fneur.2021.645706. ECollection 2021.PMID: 33841311.”. Front Neurol.

Dopaminergic Therapy for Motor Symptoms in Early Parkinson Disease Practice Guideline Summary: A Report of the AAN Guideline Subcommittee. Neurology. 2021 Nov 16;97(20):942-957. doi: 10.1212/WNL.0000000000012868. PMID: 34782410.

Publication: Journal Article

Pringsheim, T, GS Day, DB Smith, A Rae-Grant, N Licking, MJ Armstrong, RMA de Brie, et al. 2021. “Dopaminergic Therapy for Motor Symptoms in Early Parkinson Disease Practice Guideline Summary: A Report of the AAN Guideline Subcommittee. Neurology. 2021 Nov 16;97(20):942-957. Doi: 10.1212/WNL.0000000000012868. PMID: 34782410.”. Neurology.

EASE LID 2: A 2-Year Open-Label Trial of Gocovri (Amantadine) Extended Release for Dyskinesia in Parkinson's Disease. J Parkinsons Dis 2020;10:543-558.

Publication: Journal Article

Tanner, CM, R Pahwa, RA Hauser, WH Oertel, SH Isaacson, J Jankovich, R Johnson, D Chernick, and J Hubble. 2020. “EASE LID 2: A 2-Year Open-Label Trial of Gocovri (Amantadine) Extended Release for Dyskinesia in Parkinson’s Disease. J Parkinsons Dis 2020;10:543-558.”. J Parkinsons Dis.

Parkinson Disease and Orthostatic Hypotension in the Elderly: Recognition and Management of Risk Factors for Falls. Aging Dis 2020;11:679-691.

Publication: Journal Article

LeWitt, PA, S Kymes, and RA Hauser. 2020. “Parkinson Disease and Orthostatic Hypotension in the Elderly: Recognition and Management of Risk Factors for Falls. Aging Dis 2020;11:679-691.”. Aging Dis.

Caffeine, creatine, GRIN2A and Parkinson's disease progression. J Neurol Sci 2017;375:355-359.

Publication: Journal Article

Simon, DK, C Wu, BC Tilley, K Lohmann, C Klein, H Payami, AM Wills, et al. 2017. “Caffeine, Creatine, GRIN2A and Parkinson’s Disease Progression. J Neurol Sci 2017;375:355-359.”. J Neurol Sci.

Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Psychiatry 2017;4:595-604.

Publication: Journal Article

Anderson, KE, D Stamler, MD Davis, SA Factor, RA Hauser, J Isojarvi, LF Jarskog, et al. 2017. “Deutetrabenazine for Treatment of Involuntary Movements in Patients With Tardive Dyskinesia (AIM-TD): A Double-Blind, Randomised, Placebo-Controlled, Phase 3 Trial. Lancet Psychiatry 2017;4:595-604.”. Lancet Psychiatry.

Seeberger LC, Hauser RA.Valbenazine for the treatment of tardive dyskinesia. Expert Opin Pharmacother 2017;18:1279-1287.

Publication: Journal Article

Seeberger, LC, and RA Hauser. 2017. “Seeberger LC, Hauser RA.Valbenazine for the Treatment of Tardive Dyskinesia. Expert Opin Pharmacother 2017;18:1279-1287.”. Expert Opin Pharmacother.

Droxidopa and reduced falls in a trial of Parkinson patients with neurogenic orthostatic hypotension. Clin Neuropharmacol 2016;39:220-6.

Publication: Journal Article

Hauser, RA, S Heritier, GJ Rowse, LA Arthur Hewitt, and SH Isaacson. 2016. “Droxidopa and Reduced Falls in a Trial of Parkinson Patients With Neurogenic Orthostatic Hypotension. Clin Neuropharmacol 2016;39:220-6.”. Clin Neuropharmacol.

Correlates of excessive daytime sleepiness in de novo Parkinson's disease: A case control study. Mov Disord 2015;30:1371-81.

Publication: Journal Article

Simuni, T, Caspell Garcia, C Coffey, LM Chahine, S Lasch, WH Oertel, G Mayer, et al. 2015. “Correlates of Excessive Daytime Sleepiness in de Novo Parkinson’s Disease: A Case Control Study. Mov Disord 2015;30:1371-81.”. Mov Disord.